Professor
UCSF Helen Diller Family Comprehensive Cancer Center, San Francisco, CA, USA
San Francisco, California
Dr Martin is a Clinical Professor of Medicine in the Division of Hematology/Oncology, Associate Chief of Hematology/Oncology, Director of Blood and Marrow Transplantation and Cell Therapy, Director of the Hematologic Malignancies Research Site Committee, Co-Lead of the Hematopoietic Malignancies Program in the Helen Diller Family Comprehensive Cancer Center and Co-Director of the Myeloma Program at the University of California, San Francisco. His main research interests at UCSF are the development and evaluation of novel therapeutics for multiple myeloma. Dr Martin has been the pricipal investigator (PI) on over 25 clinical trials in MM. He was closely involved in the clinical development of the novel anti-CD38 monoclonal antibody, isatuximab and was the first to investigate the combination of isatuximab, carfilzomib and dexamethasone. He was also invloved in early phase studies involving the CAR T-cells, ciltacabtagene autoleucel and idecabtagene vicleucel, as well as several bispecific T-cell engaging antibodies including teclistamab and talquetamab. Dr Martin is a member of the International Myeloma Working Group (IMWG) and co-leads the immunotherapy subcommittee. He is leading the development of an international immunotherapy database project aimed at investigating the real-world implementation of novel immunotherapies. He has published numnerous articles on the treatment of relapsed and refractory multiple myeloma and presented at many national and international meetings.
Disclosure information not submitted.
Saturday, September 20, 2025
13:20 - 13:30 East Coast USA Time